Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
11
×
Tags
boston blog main
clinical trials
11
×
life sciences
national blog main
new york blog main
regeneron pharmaceuticals
11
×
boston top stories
national top stories
new york top stories
biotech
fda
san francisco blog main
san francisco top stories
amgen
san diego blog main
san diego top stories
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
inclisiran
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
rna interference
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
drugs
new york
startups
cancer immunotherapy
cystic fibrosis
What
drug
medicines
cholesterol
fda
medco
roundup
bio
lowering
week
ago
alnylam
big
biotech
disease
drugs
long
medicine
new
news
patients
prices
rna
time
twice
according
aces
acquire
adding
agreed
aiming
akcea
alliance
alzheimer’s
american
announced
annual
approve
aren’t
ash
assessed
Language
unset
Current search:
photo
×
" regeneron pharmaceuticals "
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision